Brief: Everest Medicines Enters Into Agreement With Calliditas Therapeutics To Develop And Commercialize NEFECON
14/03/2022 24:04
March 13 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ENTERS INTO AGREEMENT WITH CALLIDITAS
THERAPEUTICS, EXPANDING TERRITORY LICENSE TO DEVELOP AND
COMMERCIALIZE NEFECON IN SOUTH KOREA
Source text for Eikon: ID:nPn36CXbxa
Further company coverage: 1952.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations